|
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
|
05 November 2018 |
|
Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
|
29 October 2018 |
|
Alcon to develop SMART Suite digital health platform for cataract surgery
|
23 October 2018 |
|
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
|
16 October 2018 |
|
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
|
12 October 2018 |
|
Sandoz Healthcare Access Challenge #SandozHACk returns, seeking digital solutions to local healthcare access challenges
|
05 October 2018 |
|
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
|
03 October 2018 |
|
Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis
|
11 September 2018 |
|
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
|
06 September 2018 |
|
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)
|
27 August 2018 |